"```json\n[\n    {\n        \"source\": \"Tirzepatide\",\n        \"source_type\": \"DETAILED_DESCRIPTION\",\n        \"target\": \"Type 2 Diabetes\",\n        \"target_type\": \"DETAILED_DESCRIPTION\",\n        \"relationship\": \"TREATS\",\n        \"evidence\": \"Tirzepatide was statistically superior to insulin lispro in reducing HbA1c levels in participants with Type 2 Diabetes.\"\n    },\n    {\n        \"source\": \"Tirzepatide\",\n        \"source_type\": \"DETAILED_DESCRIPTION\",\n        \"target\": \"Body Weight\",\n        \"target_type\": \"DETAILED_DESCRIPTION\",\n        \"relationship\": \"TREATS\",\n        \"evidence\": \"Tirzepatide resulted in greater weight loss compared to insulin lispro in participants with Type 2 Diabetes.\"\n    },\n    {\n        \"source\": \"Tirzepatide\",\n        \"source_type\": \"DETAILED_DESCRIPTION\",\n        \"target\": \"Fasting Serum Glucose\",\n        \"target_type\": \"LAB_VALUE\",\n        \"relationship\": \"MEASURED_BY\",\n        \"evidence\": \"Greater reductions in fasting serum glucose were observed with all tirzepatide doses compared to insulin lispro.\"\n    },\n    {\n        \"source\": \"Tirzepatide\",\n        \"source_type\": \"DETAILED_DESCRIPTION\",\n        \"target\": \"2-hour Postprandial Glucose\",\n        \"target_type\": \"DETAILED_DESCRIPTION\",\n        \"relationship\": \"MEASURED_BY\",\n        \"evidence\": \"Reductions in mean daily 2-hour postprandial glucose levels were greater with tirzepatide compared to insulin lispro.\"\n    },\n    {\n        \"source\": \"Tirzepatide\",\n        \"source_type\": \"DETAILED_DESCRIPTION\",\n        \"target\": \"HbA1c Value\",\n        \"target_type\": \"DIAGNOSTIC_PROCEDURE\",\n        \"relationship\": \"ASSOCIATED_WITH\",\n        \"evidence\": \"More participants achieved a composite endpoint of an HbA1c value of less than 7.0% with tirzepatide treatment.\"\n    }\n]\n```"